VANCOUVER, British Columbia, April 04, 2018 (GLOBE NEWSWIRE) -- Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT: M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants. One in four Canadians suffer from anxiety and the Company through this study will seek to gain valuable information from study participants on the impact of medical cannabis use in relation to their anxiety. Namaste is also interested in determining the safety profile of patients using medical cannabis, and whether strain and dose of medical cannabis may impact patient reductions in anxiety ratings. The study will be available to all Canadians and will be conducted under the following conditions:

Prospective patients must be over 25 years of age.

Patients must score 8 or above Hospital Anxiety and Depression Scale (HADS).

The study will span over a 3-month period for each registered patient.

The study will be submitted for approval to the Veritas Independent Review Board (IRB) prior to commencement.

The primary investigator in the study is a nurse practitioner.

Patients can self-refer into the study (without referral through a doctor or specialist).

Namaste plans to offer this study to its patients which are registered under the Company’s wholly-owned subsidiary and virtual patient platform, NamasteMD Inc. (“NamasteMD”). Patients suffering from anxiety under the terms outlined above may participate in the study. This study is the first large-scale anxiety study in the nation, establishing Namaste as an innovator in research related to anxiety and cannabis. This is also the first national study where the primary investigator is a nurse practitioner. The Company intends to conduct similar studies in various areas where patients can benefit from the use of medical cannabis. The data collected from the study is valuable for the Company as well as the industry as a whole. The study may be published in peer-reviewed research journals and other medical publications.

For more information on this study please email anxiety@namastemd.com

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to have initiated this study with the help of our partners at O-Cannabis. As many people in Canada suffer from varying forms of anxiety, we believe that many of these patients can benefit from the use of medical cannabis instead of prescription pharmaceutical drugs. We hope this study will provide very valuable information for Namaste and for the industry. We encourage qualifying patients to participate and look forward to seeing the results. We plan to undertake additional studies to bring awareness and a better understanding of how medical cannabis can benefit Canadians. We believe that these studies will help Namaste by attracting a larger base of patients and help solidify Namaste’s position as a leader in the Canadian medical cannabis industry.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: info@namastetechnologies.com

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

NamasteVapes.ca

Everyonedoesit.ca

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.



